top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 4 hours ago
  • 1 min read

03/08/2026








Akebia Therapeutics announced the initiation of a Phase 2 basket trial evaluating ebribafusp in rare complement-mediated kidney disease (Ref)


Akebia Therapeutics announced the initiation of a Phase 2/ NCT06419205 basket trial evaluating the safety, efficacy and pharmacokinetics of ebribafusp (AKB-097 and ADX-097; anti-C3d factor H fusion protein) for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G).


  • The trial was expected to enroll up to 30 patients with IgAN, LN or C3G. Patients were to  receive ebribafusp dosed once-weekly subcutaneously for 26 weeks in the main study followed by a long-term extension study for responders.


  • The primary endpoint was the incidence of adverse events. Secondary endpoints included change in proteinuria measured by UPCR, kidney function measured by eGFR, and pharmacokinetics.


  • Akebia expected to report initial data in 2027.


bottom of page